SOURCE: SteadyMed Therapeutics, Inc.

SteadyMed Therapeutics, Inc.

June 10, 2013 06:00 ET

SteadyMed Therapeutics, Inc. Further Strengthens Management Team With the Addition of Peter Noymer, Ph.D., Executive Vice President of R&D and Chief Technical Officer and Rick White, Vice President Business Development and Commercial Operations

SAN FRANCISCO, CA--(Marketwired - Jun 10, 2013) - SteadyMed Therapeutics, Inc. ("SteadyMed"), a private drug delivery therapeutics company, today announced that Peter Noymer, Ph.D. has joined the company as EVP of R&D and CTO, and Rick White has joined as VP BD and Commercial Operations.

Peter is responsible for completing the development of the company's PatchPump® parenteral drug delivery technology as well as leading clinical and regulatory affairs for SteadyMed's PatchPump drug product to treat Pulmonary Arterial Hypertension (PAH). Previously, he was VP of Product R&D at Alexza Pharmaceuticals, where he worked on several development programs on combination products for novel therapies, including Adasuve®, the first inhalable treatment for acute agitation. Prior to that, he held senior management positions at Aradigm Corporation and was a Visiting Assistant Professor at Carnegie Mellon University. Peter holds a B.S.E. degree from Princeton University and M.S. and Ph.D. degrees from the Massachusetts Institute of Technology.

Rick is responsible for both Business Development activities related to the licensing of our PatchPump technology to BioPham companies, for delivery of high volume biologic products, as well as the initiation of pre-commercial activities relating to our lead PatchPump drug product to treat PAH. Rick began his Sales and Marketing career with Merck and transitioned to Astellas Pharmaceuticals where he held a number of commercially oriented positions over 23+ years including VP Critical Care Marketing and Sales. During this time Rick led several successful product launch campaigns, marketing initiatives, sales deployment activities and strategic product portfolio acquisitions. Most recently Rick was VP of BD & Marketing at Ligand Pharmaceuticals where he was successful in executing drug delivery technology licenses with both large and small Pharma companies, as well as multiple product licensing initiatives.

"Both Peter and Rick add great value and depth to our management team," said Jonathan Rigby, Chief Executive Officer of SteadyMed. "Peter will immediately focus on finishing the development of our PatchPump technology; a novel, prefilled, size efficient and disposable parenteral drug delivery system, and the execution of our clinical and regulatory program for our lead drug product to treat the life threatening orphan disease; PAH. Rick will play a critical role in licensing our PatchPump platform in response to the ever growing interest we have from BioPharm companies for biologics delivery as well as paving the way for the U.S. launch of our lead PatchPump enabled product for the treatment of PAH. We now have a strong and committed management team in place with proven capabilities and demonstrated success in the development, approval and commercialization of high value drug delivery enabled products."

About SteadyMed:

SteadyMed Therapeutics, Inc., with offices in the San Francisco Bay Area, CA and Rehovot, Israel, is a private, venture funded drug delivery therapeutics company engaged in the development for commercialization of its PatchPump® technology; a novel, prefilled, size efficient and disposable subcutaneous drug delivery system. The company's range of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner.

The company is leveraging the sustainable cost and technological competitive advantages of its PatchPump platform to create a family of products that benefits patients in target markets, which represent the highest value to risk ratios.

PatchPump® is a registered trademark of SteadyMed Ltd.

Contact Information